**In Focus**

Colorectal Cancer: Looking for Answers in the Microbiota...384
C. Jobin

**REVIEW**

The Basic Principles of Chimeric Antigen Receptor Design...388
M. Sadelain, R. Brentjens, and I. Rivière

**RESEARCH BRIEF**

Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer...399

Précis: The presence of a dysfunctional BRCA1 BRCT domain variant in trans with a known deleterious BRCA1 mutation was documented in a woman with early-onset ovarian carcinoma.
See commentary, p. 376

First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement...406

Précis: A lipid nanoparticle multitarget siRNA formulation is deliverable to tumors and shows evidence of on-target activity in patients with advanced cancers enrolled in a phase I trial.

**IN THIS ISSUE**

Highlighted research articles...363

**NEWS IN BRIEF**

Important news stories affecting the community...366

**NEWS IN DEPTH**

Q&A: Paul Workman on Big Data and Large Biases...369
Getting Across the Phase III Finish Line...370

**RESEARCH WATCH**

Selected highlights of recent articles of exceptional significance from the cancer literature...371

**ONLINE**

For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

**VIEWS**

In The Spotlight
BRCA1: A Missing Link in the Fanconi Anemia/BRCA Pathway...376
A.D. D’Andrea
See article, p. 399

Hit Parade for Adoptive Cell Transfer Therapy: The Best T Cells for Superior Clinical Responses...379
D.E. Speiser
See article, p. 418

A Model for Primary Melanoma of the CNS Implicates NRAS...382
C.A. Ciarlo and L.I. Zon
See article, p. 458

In Focus
Colorectal Cancer: Looking for Answers in the Microbiota...384
C. Jobin

**REVIEW**

The Basic Principles of Chimeric Antigen Receptor Design...388
M. Sadelain, R. Brentjens, and I. Rivière

**RESEARCH BRIEF**

Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer...399

Précis: The presence of a dysfunctional BRCA1 BRCT domain variant in trans with a known deleterious BRCA1 mutation was documented in a woman with early-onset ovarian carcinoma.
See commentary, p. 376

First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement...406

Précis: A lipid nanoparticle multitarget siRNA formulation is deliverable to tumors and shows evidence of on-target activity in patients with advanced cancers enrolled in a phase I trial.
Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy ........ 418
Précis: Single-cell immune monitoring of patients receiving adoptive cell transfer therapy reveals time-dependent changes in adoptively transferred and endogenous T-cell functionality.
See commentary, p. 379

Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non-Small Cell Lung Cancer .................. 430
Précis: Inhibition of HSP90 with ganetespib may represent an alternative or complementary therapeutic strategy for treatment of ALK-positive non-small cell lung cancer.

RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas ................. 444
Précis: RHOA-FAK signaling is a genotype-specific therapeutic target in aggressive KRAS-mutant, INK4A/ARF-deficient non-small cell lung cancers.

Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes ..... 458
Précis: Early embryonic NRAS mutation promotes melanocyte proliferation and induces early-onset primary melanoma of the central nervous system but not cutaneous melanoma.
See commentary, p. 382

Tabernero and colleagues report the results of a phase I dose-escalation and expansion study assessing the safety, activity, and pharmacodynamics of ALN-VSP, a lipid nanoparticle containing siRNAs against vascular endothelial growth factor A (VEGFA) and kinesin spindle protein (KSP), in patients with advanced solid tumors with liver involvement. One patient with metastatic endometrial cancer had a complete response and 3 patients (2 with metastatic renal cell carcinoma and 1 with metastatic pancreatic neuroendocrine tumor) experienced disease stabilization. Post-treatment tumor biopsies showed evidence of intratumoral delivery, increased VEGFA mRNA cleavage, and decreased VEGFA and KSP mRNA levels compared with pre-treatment biopsy samples, consistent with an on-target response and an RNAi mechanism of action. For details, please see the article by Tabernero and colleagues on page 406.